Form 4: Lyra Therapeutics Director Konstantin Poukalov Acquires Stock Options

Director Konstantin Poukalov acquired 30,000 stock options in Lyra Therapeutics, Inc. on June 13, 2024.

Summary

• Konstantin Poukalov, a director of Lyra Therapeutics, Inc., reported a transaction involving derivative securities.
• On June 13, 2024, Poukalov acquired 30,000 stock options with an exercise price of $0.31.
• These options vest on the earlier of June 13, 2025, or the day before the next annual meeting of stockholders after the grant date, contingent on continued service as a non-employee director.
• Following the transaction, Poukalov directly owns 30,000 derivative securities.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment, simply reporting a transaction.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company directors. It's common for directors to receive stock options as part of their compensation.

Stakeholder Impact

• The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates

Keywords

Lyra Therapeutics, Konstantin Poukalov, stock options, derivative securities, Form 4, director, beneficial ownership